(NASDAQ: INO) Inovio Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.21%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.09%.
Inovio Pharmaceuticals's earnings in 2026 is -$84,934,002.On average, 5 Wall Street analysts forecast INO's earnings for 2026 to be -$75,617,332, with the lowest INO earnings forecast at -$84,659,161, and the highest INO earnings forecast at -$57,879,222. On average, 4 Wall Street analysts forecast INO's earnings for 2027 to be -$41,827,714, with the lowest INO earnings forecast at -$77,402,661, and the highest INO earnings forecast at -$20,732,856.
In 2028, INO is forecast to generate -$9,971,516 in earnings, with the lowest earnings forecast at -$9,675,333 and the highest earnings forecast at -$10,366,428.